Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will not be available in Germany during the second quarter.
This scarcity in Europe, attributed to the drug’s weight-reducing effects, persists, as outlined in a statement posted on the website of the German healthcare regulator BfArM by Novo on Tuesday.
The company advised physicians to limit prescriptions to patients already undergoing Ozempic therapy, emphasizing the drug’s intended use in diabetes treatment.
Additionally, Novo Nordisk reiterated the importance of prescribing Ozempic strictly for approved diabetic indications.
The company pointed out ample supplies of Wegovy, an obesity medication containing the same active ingredient as Ozempic.
Despite previous assurances from Novo that the supply …
Full story available on Benzinga.com
Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will not be available in Germany during the second quarter.
This scarcity in Europe, attributed to the drug’s weight-reducing effects, persists, as outlined in a statement posted on the website of the German healthcare regulator BfArM by Novo on Tuesday.
The company advised physicians to limit prescriptions to patients already undergoing Ozempic therapy, emphasizing the drug’s intended use in diabetes treatment.
Additionally, Novo Nordisk reiterated the importance of prescribing Ozempic strictly for approved diabetic indications.
The company pointed out ample supplies of Wegovy, an obesity medication containing the same active ingredient as Ozempic.
Despite previous assurances from Novo that the supply …
Full story available on Benzinga.com
Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will not be available in Germany during the second quarter.
This scarcity in Europe, attributed to the drug’s weight-reducing effects, persists, as outlined in a statement posted on the website of the German healthcare regulator BfArM by Novo on Tuesday.
The company advised physicians to limit prescriptions to patients already undergoing Ozempic therapy, emphasizing the drug’s intended use in diabetes treatment.
Additionally, Novo Nordisk reiterated the importance of prescribing Ozempic strictly for approved diabetic indications.
The company pointed out ample supplies of Wegovy, an obesity medication containing the same active ingredient as Ozempic.
Despite previous assurances from Novo that the supply …Full story available on Benzinga.com Read MoreAI Generated, Asia, Biotech, Briefs, Large Cap, LLY, News, NVO, Stories That Matter, Eurozone, Health Care, Markets, General, LLY, US5324571083, NVO, US6701002056, News, Biotech, Asia, Large Cap, Eurozone, Health Care, Markets, General, Benzinga Asia
